Adaptimmune stock plunges after announcing Nasdaq delisting plans
NEW YORK - Pharmaceutical giant Pfizer Inc. (NYSE:PFE) announced Thursday that its board of directors has declared a fourth-quarter 2025 dividend of $0.43 per share on the company’s common stock, maintaining its attractive 6.7% dividend yield. According to InvestingPro, the company has raised its dividend for 14 consecutive years.
The dividend will be payable on December 1, 2025, to shareholders of record at the close of business on November 7, 2025, according to a company press release.
This payment represents Pfizer’s 348th consecutive quarterly dividend, continuing the company’s long-standing history of returning value to shareholders.
Pfizer, one of the world’s largest pharmaceutical companies with a market capitalization of $143.5 billion, develops and manufactures medicines and vaccines across various therapeutic areas. The company has been in operation for 175 years and maintains operations in both developed and emerging markets globally, generating revenues of $63.8 billion in the last twelve months. InvestingPro analysis suggests the stock is currently undervalued, with a GOOD overall financial health score.
The quarterly dividend announcement comes as part of the company’s regular financial operations and shareholder return program. For deeper insights into Pfizer’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks.
In other recent news, Pfizer has secured an agreement with the Trump administration to provide discounts for Medicaid programs, which BMO Capital describes as a "meaningful win" for both the company and patients. BMO Capital has reiterated an Outperform rating with a $30.00 price target on Pfizer, highlighting the significance of this deal. Additionally, TD Cowen maintains its Hold rating and $30.00 price target on Pfizer, noting the Most Favored Nation agreement as a positive development for the pharmaceutical sector, despite its modest impact. Meanwhile, Swiss pharmaceutical companies are anticipated to follow Pfizer’s lead in negotiating similar price deals with the U.S. government, according to Scienceindustries, a Swiss industry association.
In another development, Canaccord Genuity has reaffirmed its Buy rating and $24.00 price target on AxoGen, Inc., as the company faces potential challenges from the recent U.S. government shutdown. Approximately 41% of Health and Human Services employees have been furloughed, impacting the approval process for certain new applications. Despite these hurdles, AxoGen is expected to navigate the situation effectively, according to Canaccord Genuity. Lastly, the Trump administration has announced plans to launch TrumpRx.gov in early 2026, a website aimed at providing reduced prices for prescription drugs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.